Abstracts tagged "adverse events and arthritis"

Abstract Number: 619 • 2018 ACR/ARHP Annual Meeting
Patterns of Change of a Second Biological Dmard in a Cohort of Patients with Rheumatoid Arthritis
Roger Rolon Campuzano¹, Andrea Lujan Coronel Ale², Osvaldo Cerda^3,4,5, Fernando Dal Pra⁶, Emilce E Schneeberger⁷, María de los Angeles Correa³, Marcos G. Rosemffet⁸, Emilio Buschiazzo⁹, Rodrigo García Salinas¹⁰, Silvia Beatriz Papasidero¹¹, Belén Barrios¹², Hernán Maldonado Ficco¹³ and Gustavo Citera², ¹Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ²Rheumatology Section, Instituto de Rehabilitación Psicofísica, CABA, Argentina, ³Rheumatology Section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Staff, Buenos Aires, Argentina, ⁵Sociedad Argentina de Reumatologia, CABA, Argentina, ⁶Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁷Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁸Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁹Rheumatology Section, Hospital Señor del Milagro, Salta, Argentina, ¹⁰Rheumatology Section, Hospital Italiano de La Plata, La Plata, Argentina, ¹¹Rheumatology Section, Hospital General de Agudos Dr. Enrique Tornú, Argentina, Buenos Aires, Argentina, ¹²Rheumatology section, Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ¹³Rheumatology Section, Hospital San Antonio de Padua, Río Cuarto- Córdoba, Argentina
Background/Purpose: Evaluate the survival of the 2nd biological disease modifying drug (bDMARD)and to determine the causes of suspension of the 2nd bDMARD. Methods: Patients ≥…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].